Several strategies are now being pursued as potential treatments for AxD, chief among them being pharmacologic approaches for suppressing the expression of GFAP below its toxic threshold or interfering with other downstream effects of GFAP toxicity (Cho et al., 2010; Messing et al., 2010). The gene discussed is GFAP; the disease is Alexander disease.